Targeting of pericytes diminishes neovascularization and lymphangiogenesis in prostate cancer
Article first published online: 21 OCT 2005
Copyright © 2005 Wiley-Liss, Inc.
Volume 66, Issue 3, pages 294–304, 15 February 2006
How to Cite
Ozerdem, U. (2006), Targeting of pericytes diminishes neovascularization and lymphangiogenesis in prostate cancer. Prostate, 66: 294–304. doi: 10.1002/pros.20346
- Issue published online: 3 JAN 2006
- Article first published online: 21 OCT 2005
- Manuscript Accepted: 9 AUG 2005
- Manuscript Received: 24 MAY 2005
- US Department of Defense Prostate Cancer Research Program/Congressionally Directed Medical Research New Investigator Award. Grant Number: PC020822
- NIH (National Institute of Child Health and Human Development). Grant Number: RO3 HD044783
- University of California Tobacco-Related Disease Research Program Idea Award (to UO). Grant Number: TRDRP 13IT-0067
The walls of capillaries in prostate cancer are composed of endothelial cells, and pericytes. NG2 is a transmembrane proteoglycan on nascent pericytes with a functional role in neovascularization.
The anti-angiogenic effect of hydron pellets containing NG2 neutralizing antibody was quantified in intracorneal PC-3 and LNCaP xenografts. TRAMP and TRAMP-C1 tumors grafted in NG2 knockout mice represented intrinsic pericyte targeting. TRAMP and TRAMP-C1 grafts were analyzed with confocal microscope for microvascular density (MVD) and lymphatic vascular density (LVD).
NG2 neutralizing antibody decreased corneal neovascularization in PC3 (P < 0.0001), and LNCaP (P = 0.0079) xenografts. Mean MVD in TRAMP and TRAMP-C1 tumors in NG2 knockout mice were 71% (P = 0.0006) and 63% (P = 0.0011) lower than wild type controls, respectively. Mean LVD in TRAMP and TRAMP-C1 tumors in NG2 knockout mice were 73% (P = 0.0003) and 84% (P < 0.0001) lower than wild type controls, respectively.
Targeting of pericyte-NG2 decreases neovascularization and lymphangiogenesis in prostate cancer significantly. © 2005 Wiley-Liss, Inc.